Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Gatfield, John ^a   Mueller Grandjean, Celia ^a   Sasse, Thomas ^a   Clozel, Martine ^a   Nayler, Oliver ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; INOSITOL PHOSPHATE; MACITENTAN;

ANIMAL CELL; ARTICLE; BINDING KINETICS; CALCIUM TRANSPORT; CONTROLLED STUDY; DISSOCIATION; DRUG POTENCY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG ALVEOLUS CELL; NONHUMAN; PULMONARY ARTERIAL SMOOTH MUSCLE CELL;

ANIMALS; CALCIUM; CHO CELLS; CLINICAL TRIALS, PHASE III AS TOPIC; CRICETINAE; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; INOSITOL PHOSPHATES; MYOCYTES, SMOOTH MUSCLE; PHENYLPROPIONATES; PULMONARY ARTERY; PYRIDAZINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 84867562420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047662     Document Type: Article

References (53)

1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537.
2. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, et al. (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22: 405-418.
3. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, et al. (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54: S20-31.
4. Archer SL, Weir EK, Wilkins MR, (2010) Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 121: 2045-66.
5. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, et al. (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122: 156-163.
6. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-1739.
7. Shao D, Park JE, Wort SJ, (2011) The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 63: 504-511.
8. Schiffrin EL, Touyz RM, (1998) Vascular biology of endothelin. J Cardiovasc Pharmacol 32: S2-13.
9. Iglarz M, Clozel M, (2007) Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 50: 621-628.
10. Price LC, Howard LS, (2008) Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy. Am J Cardiovasc Drugs 8: 171-185.
11. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, et al. (1988) Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 238: 249-252.
12. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, et al. (2000) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157: 1703-1711.
13. Leask A, (2011) The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis. Pharmacol Res 63: 502-503.
14. Hosoda K, Nakao K, Arai H, Suga S, Ogawa Y, et al. (1991) Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 287: 23-26.
15. Ogawa Y, Nakao K, Arai H, Nakagawa O, Hosoda K, et al. (1991) Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 178: 248-255.
16. Bouallegue A, Daou GB, Srivastava AK, (2007) Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 5: 45-52.
17. Russell FD, Skepper JN, Davenport AP, (1998) Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. J Cardiovasc Pharmacol 31: 424-430.
18. Russell FD, Davenport AP, (1999) Secretory pathways in endothelin synthesis. Br J Pharmacol 126: 391-398.
19. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, et al. (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 267: 16066-16068.
20. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA, (2001) Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 276: 12645-12653.
21. Kanse SM, Takahashi K, Warren JB, Ghatei M, Bloom SR, (1991) Glucocorticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells. Eur J Pharmacol 199: 99-101.
22. Rodríguez-Pascual F, Reimunde FM, Redondo-Horcajo M, Lamas S, (2004) Transforming growth factor-beta induces endothelin-1 expression through activation of the Smad signaling pathway. J Cardiovasc Pharmacol 44: S39-42.
23. Malek AM, Greene AL, Izumo S, (1993) Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A 90: 5999-6003.
24. Malek AM, Zhang J, Jiang J, Alper SL, Izumo S, (1999) Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J Mol Cell Cardiol 31: 387-399.
25. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, et al. (1999) Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol 55: 902-909.
26. Haynes WG, Webb DJ, (1998) Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098.
27. Janakidevi K, Fisher MA, Del Vecchio PJ, Tiruppathi C, Figge J, et al. (1992) Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 263: C1295-1301.
28. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH, et al. (2002) ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 165: 398-405.
29. Tajsic T, Morrell NW (2010) Smooth Muscle Cell Hypertrophy, Proliferation, Migration and Apoptosis in Pulmonary Hypertension. Compr Physiol: 295-317.
30. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, et al. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327: 736-745.
31. Cheng Y, Prusoff WH, (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
32. Kenakin T, Jenkinson S, Watson C, (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723.
33. Pollock DM, Keith TL, Highsmith RF, (1995) Endothelin receptors and calcium signaling. FASEB J 9: 1196-1204.
34. Shimoda LA, Sylvester JT, Sham JS, (2000) Mobilization of intracellular Ca(2+) by endothelin-1 in rat intrapulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 278: L157-164.
35. Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, et al. (2000) Endothelin-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension 35: 280-286.
36. Kuhr FK, Smith KA, Song MY, Levitan I, Yuan JX, (2012) New mechanisms of pulmonary arterial hypertension: role of Ca2+ signaling. Am J Physiol Heart Circ Physiol 302: H1546-1562.
37. Le MT, Pugsley MK, Vauquelin G, Van Liefde I, (2007) Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 151: 952-962.
38. Vauquelin G, Charlton SJ, (2010) Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488-508.
39. Swinney DC, (2006) Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. Curr Top Med Chem 6: 461-478.
40. Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, et al. (2002) Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol 449: 229-37.
41. Herbert JM, Savi P, (2003) P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 3: 113-122.
42. Gradman AH, (2002) AT(1)-receptor blockers: differences that matter. J Hum Hypertens 16: S9-S16.
43. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, et al. (2011) Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 337: 600-609.
44. De Mey JG, Compeer MG, Lemkens P, Meens MJ, (2011) ETA-receptor antagonists or allosteric modulators? Trends Pharmacol Sci 32: 345-351.
45. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV Jr, et al. (1998) Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98: 1400-1406.
46. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A, et al. (2001) Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol 280: H746-755.
47. Platoshyn O, Golovina VA, Bailey CL, Limsuwan A, Krick S, et al. (2000) Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol 279: C1540-1549.
48. Berridge MJ, (1993) Inositol trisphosphate and calcium signalling. Nature 361: 315-25.
49. Hardingham GE, Chawla S, Johnson CM, Bading H, (1997) Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 385: 260-265.
50. Dickinson KE, Tymiak AA, Cohen RB, Liu EC, Webb ML, et al. (1991) Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase. Biochem Biophys Res Commun 176: 423-430.
51. Edano T, Arai K, Ohshima T, Koshi T, Hirata M, et al. (1994) Purification and characterization of endothelin-1 degradation activity from porcine kidney. Biol Pharm Bull 17: 379-382.
52. Battistini B, Brown M, Vane JR, (1995) Selective proteolitic activation and degradation of ETs and big ETs in parenchymal strips of the guinea-pig lung. Biochem Biophys Res Commun 207: 675-81.
53. Pérez-Vizcaíno F, Cooper AC, Corder R, Fournier A, Warner TD, (1995) Rapid degradation of endothelin-1 by an enzyme released by the rat isolated perfused mesentery. Br J Pharmacol 114: 867-871.